Cited by 154Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchNeutropenia and Cancer Infections

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Open access

Rummel, M., Kim, T.M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., Grigg, A.·2017·Annals of Oncology

DOI 10.1093/annonc/mdw685

Open this paper in CoChat — free account Open PDF

Abstract

Background The aim of this study was to evaluate patient preference and satisfaction for the subcutaneous (s.c.) versus intravenous (i.v.) formulation of rituximab given with chemotherapy in previously untreated patients with CD20+ diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).Patients and methods Patients received eight cycles of rituximab according to 2 schedules: Arm A received 1 cycle rituximab i.v. (375 mg/m2) and 3 cycles rituximab s.c. (1400 mg) then 4 cycles rituximab i.v.; Arm B received 4 cycles rituximab i.v. (375 mg/m2) then 4 cycles rituximab s.c. (1400 mg). Alongside rituximab, both arms received 6-8 cycles of chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), cyclophosphamide, vincristine, prednisone (CVP), or bendamustine as per standard local practice). Preference for s.c. or i.v. administration was evaluated using the Patient Preference Questionnaire (PPQ) at cycles 6 and 8. Patient satisfaction and convenience were assessed using the Cancer Therapy Satisfaction Questionnaire (CTSQ), and Rituximab Administration Satisfaction Questionnaire (RASQ) at cycles 4 and 8.Results At the primary data cut-off (19 January 2015), the intent-to-treat population comprised 743 patients. The majority had DLBCL (63%) and baseline characteristics were balanced between arms. At cycle 8, 81% of patients completing the PPQ preferred rituximab s.c. Preference was not impacted by treatment sequence or disease type. Patient satisfaction as measured by RASQ was higher for s.c. versus i.v. CTSQ scores were similar between arms. Adverse events were generally balanced between administration routes and no new safety signals were detected.Conclusion Most previously untreated patients with CD20+ DLBCL or FL preferred s.c. to i.v. rituximab administration. Patient satisfaction with rituximab treatment was generally greater with s.c. administration.Registered clinical trial number NCT01724021 (ClinicalTrials.gov).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw685

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Coiffier, B., Thiéblemont, C., Neste, É. V. D., Lepeu, G., Plantier, I., Castaigné, S., Lefort, S., Marit, G., Macro, M., Sebban, C., et al. (2010) · Blood · doi:10.1182/blood-2010-03-276246 · Cited by 1,539
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512
Self-citation
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,317
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
Marcus, R. E. (2004) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 972
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Self-citation
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu364 · Cited by 177
Self-citation
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138

Show all 15 references

Research works printed but not linked: 2

Lugtenburg, 2015, Subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated diffuse large B-cell lymphoma: efficacy and safety results from the phase IIIB MABEASE study, Haematologica, 100, S483
Lugtenburg, 2015, Patient preference with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the phase IIIb MABEASE study, Hematol Oncol, 33, A383

Sorted by citations

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Tan, A. R., Im, S., Mattar, A. P. L., Colomer, R., Stroyakovskiy, D., Nowecki, Z. I., Laurentiis, M. D., Pierga, J., Jung, K. H., Schem, C., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30536-2 · Cited by 186
ENHANZE ® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20
Locke, K. W., Maneval, D. C., & LaBarre, M. J. (2019) · Drug Delivery · doi:10.1080/10717544.2018.1551442 · Cited by 177
Anti-CD20 monoclonal antibodies: reviewing a revolution
Casan, J. M. L., Wong, J., Northcott, M., & Opat, S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1508624 · Cited by 139
Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements
Badkar, A. V., Gandhi, R. B., Davis, S. P., & LaBarre, M. J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s287323 · Cited by 133
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125
Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
Davis, J. D., Padros, M. B., Conrado, D. J., Ganguly, S., Guan, X., Hassan, H. E., Hazra, A., Irvin, S. C., Jayachandran, P., Kosloski, M. P., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3150 · Cited by 124
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study
O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.047 · Cited by 83
Self-citation
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Lugtenburg, P. J., Avivi, I. M., Berenschot, H. W., İlhan, O., Marolleau, J. P., Nagler, A., Rueda, A., Tani, M., Turgut, M., Osborne, S., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.173583 · Cited by 75
Self-citation
Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors
Johnson, M. L., Braiteh, F., Grilley‐Olson, J. E., Chou, J., Davda, J. P., Forgie, A. J., Li, R., Jacobs, I. A., Kazazi, F., & Hu‐Lieskovan, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0836 · Cited by 74
Humanistic and Economic Impact of Subcutaneous Versus Intravenous Administration of Oncology Biologics
Anderson, K. C., Landgren, O., Arend, R. C., Chou, J., & Jacobs, I. A. (2019) · Future Oncology · doi:10.2217/fon-2019-0368 · Cited by 69
Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Davies, A. J., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P. J., Rule, S. A., Rummel, M., McIntyre, C., Smith, R. B. W., & Badoux, X. C. A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0610-z · Cited by 67
Self-citation
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Klein, C., Jamois, C., & Nielsen, T. G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1822318 · Cited by 68
Subcutaneous drug delivery from nanoscale systems
Tomasini, L., Ferrere, M., & Nicolas, J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00161-w · Cited by 59
Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review
Janssens, R., Huys, I., van Overbeeke, E., Whichello, C. L., Harding, S., Kübler, J., Juhaeri, J., Ciaglia, A., Simoens, S., Stevens, H., et al. (2019) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-019-0875-z · Cited by 57
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications
Burotto, M., Zvirbule, Z., Mochalova, A., Runglodvatana, Y., Herraez-Baranda, L., Liu, S. N., Chan, P., Shearer-Kang, E., Liu, X., Tosti, N., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.009 · Cited by 56
Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery
Knowles, S. P., Printz, M. A., Kang, D. W., LaBarre, M. J., & Tannenbaum, R. P. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1981286 · Cited by 54
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility
Gnanasakthy, A., Norcross, L., DeMuro, C., & Carson, R. T. (2021) · Value in Health · doi:10.1016/j.jval.2021.10.006 · Cited by 49
Building from Patient Experiences to Deliver Patient-Focused Healthcare Systems in Collaboration with Patients: A Call to Action
Schroeder, K., Bertelsen, N., Scott, J., Deane, K. H., Dormer, L., Nair, D., Elliott, J., Krug, S., Sargeant, I., Chapman, H., et al. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00432-x · Cited by 52
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.012 · Cited by 40
The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management
Jackson, Y., Janssen, E. M., Fischer, R. A., Beaverson, K. L., Loftus, J., Betteridge, K., Rhoten, S. E., Flood, E. M., & Lundie, M. J. (2019) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1612242 · Cited by 40
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
Kirschbrown, W. P., Wynne, C., Kågedal, M., Wada, R., Li, H., Wang, B., Nijem, I., Črnjević, T. B., Gasser, H., Heeson, S., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1362 · Cited by 38
Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands
Franken, M. G., Kanters, T. A., Coenen, J. L., de Jong, P., Koene, H. R., Lugtenburg, P. J., Jager, A., & Uyl-de Groot, C. A. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000648 · Cited by 37
Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access
Bittner, B., & Schmidt, J. (2023) · BioDrugs · doi:10.1007/s40259-023-00626-1 · Cited by 37
The investigation and management of follicular lymphoma
McNamara, C., Montoto, S., Eyre, T. A., Ardeshna, K. M., Burton, C., Illidge, T., Linton, K., Rule, S. A., Townsend, W. M., Wong, W. L., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16872 · Cited by 35
Subcutaneous Administration of a Zwitterionic Chitosan‐Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies
Gréa, T., Jacquot, G., Durand, A., Mathieu, C., Gasser, A., Zhu, C., Banerjee, M., Hucteau, E., Mallard, J., Navarro, P. L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308738 · Cited by 36
Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer
Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106613 · Cited by 35
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
Xu, Z., Leu, J. H., Xu, Y. C., Nnane, I. P., Liva, S. G., Wang‐Lin, S. X., Kudgus-Lokken, R., Vermeulen, A., & Ouellet, D. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2823 · Cited by 34
Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma
Harvey, M. J., Zhong, Y., Morris, E., Beverage, J. N., Epstein, R. S., & Chawla, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261336 · Cited by 33
Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions
Schneider, A., Jost, R., Jordi, C., & Lange, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2219891 · Cited by 34
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
Albiges, L., Bourlon, M. T., Chacón, M., Cutuli, H. J., Chuken, Y. A. L., Żurawski, B., Mota, J. M., Magri, I., Burotto, M., Luz, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.09.002 · Cited by 31
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Usmani, S. Z., Mateos, M., Hungria, V., Iida, S., Bahlis, N. J., Nahi, H., Magen, H., Cavo, M., Hulin, C., White, D. J., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03365-w · Cited by 31
Flexible care in breast cancer
Wardley, A. M., Canon, J. L., Elsten, L., Murillo, C. P., Črnjević, T. B., Fredriksson, J., & Piccart, M. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100007 · Cited by 28
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Felip, E., Burotto, M., Zvirbule, Z., Herráez-Baranda, L. A., Chanu, P., Kshirsagar, S. A., Maiya, V., Chan, P., Pozzi, E., Marchand, M., et al. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.936 · Cited by 28
Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology
Jacquot, G., Navarro, P. L., Grange, C., Boudali, L., Harlepp, S., Pivot, X. B., & Detappe, A. (2024) · Advanced Materials · doi:10.1002/adma.202406604 · Cited by 26
Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
CHANG, M. A., Kapre, A., Kaufman, D., Kardatzke, D. R., Rabena, M., Patel, S., Bobbala, A., Gune, S., Fung, A. E., & Wallenstein, G. V. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.1091 · Cited by 26
Modeling and prediction of excipient and pH drifts during ultrafiltration/diafiltration of monoclonal antibody biotherapeutic for high concentration formulations
Hebbi, V., Roy, S., Rathore, A. S., & Shukla, A. (2019) · Separation and Purification Technology · doi:10.1016/j.seppur.2019.116392 · Cited by 25
Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design
Stevenson, J., Poker, R., Schoss, J., Campbell, M., Everitt, C., Holly, B., Stones, N., Pettis, R. J., & Sánchez-Félix, M. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115322 · Cited by 26
Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
Theodore‐Oklota, C., Humphrey, L., Wiesner, C., Schnetzler, G., Hudgens, S. A., & Campbell, A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s108489 · Cited by 23
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Ailawadhi, S., Špıčka, I., Spencer, A. G., Lu, J., Oriol, A., Ling, S., Schjesvold, F. H., Berkovits, A., Hus, M., Li, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00744 · Cited by 22
Subcutaneous Injection Performance in Yucatan Miniature Pigs with and without Human Hyaluronidase and Auto-injector Tolerability in Humans
Shi, G. H., Connor, R., Collins, D. S., & Kang, D. W. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-020-01880-0 · Cited by 23
Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review
Jolles, S. R. A., Giralt, S., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Ria, R., & Vinh, D. C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098326 · Cited by 23
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low–Tumor Burden Follicular Lymphoma: Results of a LYSA Study
Cartron, G., Bachy, E., Tilly, H., Daguindau, N., Pica, G.-M., Bijou, F. D., Mounier, C., Clavert, A., Damaj, G. L., Slama, B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02327 · Cited by 22
Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
Gibiansky, E., Gibiansky, L. V., Chavanne, C., Frey, N., & Jamois, C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12665 · Cited by 21
The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States
Levitan, B. S., Hauber, B., Damiano, M. G., Jaffe, R., & Christopher, S. A. (2017) · Patient · doi:10.1007/s40271-017-0272-6 · Cited by 21
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-017-3147-y · Cited by 20
Differences Between Intravenous and Subcutaneous Modes of Administration in Oncology from the Patient, Healthcare Provider, and Healthcare System Perspectives: A Systematic Review
Aguiar-Ibáñez, R., Fotheringham, I., Mittal, L., Sillah, A., & Pathak, S. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02985-9 · Cited by 19
An industry perspective on hyaluronidase co-formulated biopharmaceutics
Guo, J., Weng, J., Zhou, F., & Gu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.069 · Cited by 18
Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: A clinical, economic and patient perspective
George, S., Bourlon, M. T., Overman, M. J., Dixon, M., Shelley, K., Markus, K. J., Kewley, R. M., Pope, S. I., & Albiges, L. K. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102974 · Cited by 19
Mitigating time toxicity in lymphoma and multiple myeloma
Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 18
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
Waks, A. G., Chen, E., Graham, N., Frey, A., Almeida, K., Attaya, V., Ryding, C., Abbass, I. M., Fung, A., Sussell, J. A., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00021 · Cited by 17
Issues in the Design of Discrete Choice Experiments
Norman, R., Craig, B. M., Hansen, P., Jonker, M. F., Rose, J. M., Street, D. J., & Mulhern, B. J. (2018) · Patient · doi:10.1007/s40271-018-0346-0 · Cited by 17
Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study
García‐Muñoz, R., Quero, C., Persona, E. P., Domingo‐García, A., Pérez‐López, C., Villaescusa‐de‐la‐Rosa, T., Martínez‐Castro, A. M., Arguiñano‐Pérez, J. M., Parra‐Cuadrado, J. F., & Panizo, C. (2019) · British Journal of Haematology · doi:10.1111/bjh.16227 · Cited by 17
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
Parnes, A. D., Mahlangu, J. N., Pipe, S. W., Paz‐Priel, I., Lehle, M., Trask, P. C., & Jiménez‐Yuste, V. (2021) · Haemophilia · doi:10.1111/hae.14421 · Cited by 17
Self-citation
Formative Study on the Wearability and Usability of a Large-Volume Patch Injector
Lange, J., Schneider, A., Jordi, C., Lau, M., & Disher, T. C. (2021) · Medical Devices Evidence and Research · doi:10.2147/mder.s337670 · Cited by 17
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC
Burotto, M., Zvirbule, Z., Alvarez, R., Chewaskulyong, B., Herráez-Baranda, L. A., Shearer-Kang, E., Liu, X., Tosti, N., Williams, P. T., Sanchez, A. Y. C., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.05.005 · Cited by 17
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
van Deen, W. K., Khalil, C., Bonthala, N. N., Gale, R., Patel, D. B., Warui, E., MELMED, G. Y., & Spiegel, B. M. R. (2022) · Digestive Diseases · doi:10.1159/000528586 · Cited by 15
The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology
Altini, M., Gentili, N., Balzi, W., Musuraca, G., Maltoni, R., Masini, C., Galardi, F., Bertoni, L., & Massa, I. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1764353 · Cited by 15
Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis
Singer, B. A., Morgan, D., Stamm, J. A., & Williams, A. A. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00654-1 · Cited by 14
Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review
Parra, A., Hernandez, C. A., & Prieto‐Pinto, L. (2023) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2249232 · Cited by 16
Customer-centric product presentations for monoclonal antibodies
Bittner, B. (2023) · AAPS Open · doi:10.1186/s41120-022-00069-y · Cited by 12
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations
Hadfield, M. J., Benjamin, D. J., Krell, J., Warner, J. L., & Lythgoe, M. P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.03.006 · Cited by 13
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
Sánchez, O. D., Gutierrez, A. M., do Pazo-Oubiña, F., Ginés, J., Martorell, C. N., Vallespir, B. B., Bento, L., García‐Recio, M., & Sampol, A. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s212257 · Cited by 13
Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s Disease
Benz, H. L., Caldwell, B., Ruiz, J. P., Saha, A., Ho, M., Christopher, S. A., Bardot, D. M., Sheehan, M., Donnelly, A. C., McLaughlin, L., et al. (2021) · MDM Policy & Practice · doi:10.1177/23814683211021380 · Cited by 13
Development roadmap for subcutaneous delivery of high dose biologics - high concentration formulation, analytical comparability and patient preference considerations for large volume devices
Ghosh, I., Miranda, D., Kulkarni, T. A., Deodhar, S., Tummala, S., & Bindra, D. S. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103914 · Cited by 12
Identifying a predictive relationship between maximal flow rate and viscosity for subcutaneous administration of macromolecules with recombinant human hyaluronidase PH20 in a miniature pig model
Connor, R., Clift, R., & Kang, D. W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2252999 · Cited by 12
Subcutaneous Rituximab with Recombinant Human Hyaluronidase in the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hill, S. L., & Davies, A. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0574 · Cited by 12
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma
Quach, H., Parmar, G., Mateos, M., Ailawadhi, S., & Leleu, X. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.004 · Cited by 11
Immunobiologicals in dermatology
da Silva, D. L. F., Secamilli, E. N., Beleli, M. V., Serrano, J. Y. M., França, A. F. E. D. C., & Magalhães, R. F. (2022) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2021.05.016 · Cited by 37
Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis
Si, T., Ma, X., Zhu, W., & Zhou, Y. (2023) · Hematology · doi:10.1080/16078454.2023.2284047 · Cited by 10
Development pathways for subcutaneous formulations of biologics versus biosimilar development
Zharkov, A., Barton, B., Heinzmann, D., Bakalos, G., & Schreitmüller, T. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1585806 · Cited by 10
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda
Luo, J., Nishikawa, G., & Prasad, V. K. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02984-2 · Cited by 10
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer
Chan, P., Liu, S. N., Gosselin, N. H., Sauvé, Z., Marchand, M., Lin, A., Herráez-Baranda, L. A., Zanghi, J. A., Shearer-Kang, E., Liu, X., et al. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13310 · Cited by 10
Efficacy of subcutaneous preemptive rituximab in immune‐mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases
Delrue, M., Baylatry, M. T., Joly, A., Corre, E., Marjanovic, Z., Khoury, N., Féger, F., Suner, L., Veyradier, A., Stépanian, A., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26022 · Cited by 9
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies
Jamois, C., Gibiansky, E., Gibiansky, L. V., Chavanne, C., Morcos, P. N., McIntyre, C., Barrett, M., Lundberg, L., Zharkov, A., Boehnke, A., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2308 · Cited by 9
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study
Rule, S. A., Barreto, W. G., Briones, J., Carella, A. M., Casasnovas, O., Pocock, C., Wendtner, C., Zaja, F. F., Robson, S., MacGregor, L., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.274803 · Cited by 9
Update on the Subcutaneous Administration of Rituximab in Canadian Cancer Centres
Stewart, D. A., Aucoin, J.-S., Crosbie, T., Forman, M., Lye, E., Christofides, A., & Mitha, A. (2020) · Current Oncology · doi:10.3747/co.27.6041 · Cited by 9
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia
Wallace, D. S., Zent, C. S., Baran, A. M., Reagan, P. M., Casulo, C., Rice, G., Friedberg, J. W., & Barr, P. M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009382 · Cited by 9
Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites
Stewart, D. A., Boudreault, J., Maturi, B., Boras, D., & Foley, R. (2018) · Current Oncology · doi:10.3747/co.25.4231 · Cited by 9
Subcutaneous delivery of immune checkpoint inhibitors: new route replacing intravenous administration?
Inoue, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-63 · Cited by 12
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Ghosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J. P., Morrissey, M., Fraser, K., Perati, S., Cox, B. F., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008837 · Cited by 8
Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution
Milewski, M., Murashov, M. D., Kapoor, Y., Zhang, J., Zhu, W., Cueto, M. A., & Buist, N. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00132 · Cited by 8
A phase I clinical study to evaluate rapid, high-volume, subcutaneous auto-injector tolerability with recombinant human hyaluronidase
Kang, D. W., Connor, R., Nekoroski, T., Bitsura, J. A. M., Kindig, S. K., Knowles, S. P., & LaBarre, M. J. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01883-z · Cited by 9
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
Alexander, M., Cheng, Y., Lee, S.-H., Passaro, A., Spira, A. I., Cho, B. C., Lim, S. M., Ohe, Y., Nagrial, A. M., Tan, J. L., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115624 · Cited by 9
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18
Cohen, G. L., Coetzee, C., Walton, C. A., Reig, Ò., Cho, B. C., McAdam, G. L., Rojas, C. I., Rodríguez, L. M., Pápai, Z., Chan, S. W., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115709 · Cited by 10
Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework
Bittner, B. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2184343 · Cited by 8
Bénéfices médicoéconomiques des formes sous-cutanées de trastuzumab et de rituximab en hospitalisation de jour (étude SCuBA)
Favier, M., Le Goc-Sager, F., Vincent-Cantini, I., Launay, V., Giroux, E.-A., Lièvremont, K., Bonnet, I., Barbe, C., Duval, E., Loric, N., et al. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.07.014 · Cited by 7
Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis
Zietse, M., Kooijman, T., Malmberg, R., Spierings, L. E. A. M. M., Jager, A., Mathijssen, R. H. J., van Leeuwen, R. W. F., & Thielen, F. W. F. (2025) · JCO Oncology Practice · doi:10.1200/op-24-00804 · Cited by 8
Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes
Fei, X., Pei, J., Yan, S., Ge, W., Li, L., Jianjun, Z., Zhang, H., Sun, L., Han, S., & Hu, L. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.104026 · Cited by 7
Current Practices and Challenges When Submitting Patient Experience Data for Regulatory Decisions by the US Food and Drug Administration: An Industry Survey
Pinto, C. A., Tervonen, T., Jimenez‐Moreno, C., Levitan, B. S., Soriano‐Gabarró, M., Girman, C. J., Norquist, J. M., & Hauber, B. (2023) · Patient · doi:10.1007/s40271-023-00653-8 · Cited by 7
A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer
Ziegengeist, J. L., & Tan, A. R. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.10.005 · Cited by 6
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
Cappuzzo, F., Zvirbule, Z., Korbenfeld, E. P., Kołb-Sielecki, J., Isla, D., Szczęsna, A., Sanchez, A. Y. C., Bustillos, A., Liu, X., Young, F. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100815 · Cited by 7
Development and Preclinical Testing of a Rapid, High-Volume, Auto-Injector for Subcutaneous Administration with Recombinant Human Hyaluronidase
Connor, R., Nekoroski, T., & Kang, D. W. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03116-5 · Cited by 7
Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors
Cui, C., Wang, J., Wang, C., Xu, T., Qin, L. F., Xiao, S., Gong, J., Song, L., & Liu, D. (2024) · The Oncologist · doi:10.1093/oncolo/oyae102 · Cited by 6
Preferences of patients and physicians in the United States for relapsed/refractory follicular lymphoma treatments
Thomas, C., Marsh, K., Trapali, M., Krucien, N., Worth, G. M., Cockrum, P. C., & Lycett, D. (2024) · Cancer Medicine · doi:10.1002/cam4.70177 · Cited by 6
Reducing treatment toxicity in Waldenström macroglobulinemia
Sarosiek, S., Treon, S. P., & Castillo, J. J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1897565 · Cited by 6
Subcutaneous Administration: Evolution, Challenges, and the Role of Hyaluronidase
Eisenberg, S. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.663-671 · Cited by 7
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Cho, B. C., Penkov, K., Bondarenko, I., Kurochkin, A., Pikiel, J., Ahn, H. K., Korozan, M., Osipov, M., Odintsova, S., Braiteh, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101589 · Cited by 6
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
Ozawa, Y., Hicks, K. C., Minnar, C. M., Knudson, K. M., Schlom, J., & Gameiro, S. R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1915561 · Cited by 6
Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice
Frade‐Sosa, B., Salman-Monte, T. C., Narváez, J., Peralta, I., Sandoval, S., Magallares, B., Heredia, S., Sapena, N., Riveros-Frutos, A., Olivé, A., et al. (2024) · Lupus · doi:10.1177/09612033241237560 · Cited by 5

Authors: Rummel, M., Kim, T. M., Aversa, F., Brugger, W., Capochiani, E., Plenteda, C., Re, F., Trask, P., Osborne, S., Smith, R., & Grigg, A.
Affiliations: Universitätsklinikum Gießen und Marburg (DE)
Seoul National University Hospital (KR)
University of Parma (IT)
University of Freiburg (DE)
Ospedale di Livorno (IT)
Genentech (US)
F. Hoffmann-La Roche AG (CH)
Austin Hospital (AU)
Corresponding author: Rummel, M.
ORCID: Rummel, M.
Kim, T.M.
Aversa, F.
Capochiani, E.
Grigg, A.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2017-04
Volume: 28
Issue: 4
Pages: 836-842
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw685
OpenAlex: W2566995909
Cited by: 154
References: 15
Citations by year: 2026: 16 · 2025: 30 · 2024: 20 · 2023: 18 · 2022: 10 · 2021: 22 · 2020: 9 · 2019: 11 · 2018: 10 · 2017: 7
FWCI: 8.77
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 942 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: F. Hoffmann-La Roche Ltd
Topics: Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
Keywords: rituximab, subcutaneous administration, intravenous administration, patient preferences, patient satisfaction, diffuse large B-cell lymphoma, follicular lymphoma, CD20-positive lymphoma, CHOP chemotherapy, bendamustine, treatment-naive patients, crossover trial, adverse events
MeSH terms: Rituximab, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Infusions, Intravenous, Lymphoma, Follicular, Male, Middle Aged, Prospective Studies, Lymphoma, Large B-Cell, Diffuse, Cross-Over Studies, Infusions, Subcutaneous, Patient Preference

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks